FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1791755430> ?p ?o ?g. }

• W1791755430 endingPage "362" @default.
• W1791755430 startingPage "351" @default.
• W1791755430 abstract "// Liliana H. Mochmann 1 , Martin Neumann 1 , Eva K. von der Heide 1 , Verena Nowak 2 , Anja A. Kühl 3 , Jutta Ortiz-Tanchez 1 , Juliane Bock 1 , Wolf K. Hofmann 2 , Claudia D. Baldus 1 1 Department of Hematology and Oncology, Charité University Medicine Berlin, Berlin, Germany 2 Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany 3 Department of Gastroenterology, Infectiology and Rheumatology, Charité University Medicine Berlin, Berlin, Germany Correspondence: Claudia D. Baldus, email: // Keywords : ERG, ERK, EMT, Chemoresistance Received : September 26, 2013 Accepted : December 3, 2013 Published : December 4, 2013 Abstract Overexpression of the oncogene ERG (ETS-related gene) is an adverse prognostic factor in acute myeloid and T-cell lymphoblastic leukemia (AML and T-ALL). We hypothesize that ERG overexpression is associated with primary drug resistance thereby influencing the outcome in leukemia. We previously reported a cell-line based model of ERG overexpression which induced a potentially chemo-resistant spindle shape cell type. Herein, we report a specific transcriptional gene signature for the observed spindle shaped morphology. Genes significantly over-expressed after ERG induction strongly resembled adhesive mesenchymal-like genes that included integrins (ITGA10, ITGB5, ITGB3, ITGA2B), CD44, and CD24. Interestingly, the mesenchymal-like signature was accompanied by the repression of DNA chromatin remodeling and DNA repair genes, such as CHEK1, EZH2, SUZ12, and DNMT3a. The ERG-induced mesenchymal-like signature positively correlated with TMPRSS2-ERG prostate tissues and invasive breast cancer mRNA expression datasets reflecting a general ERG-driven pattern of malignancy. Furthermore, inhibitors modulating ERG druggable pathways WNT, PKC, and AKT, and chemotherapeutic agent cytarabine revealed ERG-induced drug resistance. In particular, PKC412 treatment enhanced proliferative rates and promoted spindle shape formation in ERG-induced cells. Nilotinib and dasatinib were effective at abolishing ERG-induced cells. Moreover, ERG overexpression also led to an increase in double strand breaks. This report provides mechanistic clues into ERG-driven drug resistance in the poor prognostic group of high ERG expressers, provides insight to improved drug targeted therapies, and provides novel markers for a mesenchymal-like state in acute leukemia." @default.
• W1791755430 created "2016-06-24" @default.
• W1791755430 creator A5012626021 @default.
• W1791755430 creator A5016198812 @default.
• W1791755430 creator A5029305848 @default.
• W1791755430 creator A5029609160 @default.
• W1791755430 creator A5035426042 @default.
• W1791755430 creator A5052795429 @default.
• W1791755430 creator A5071516377 @default.
• W1791755430 creator A5080023346 @default.
• W1791755430 creator A5091178280 @default.
• W1791755430 date "2013-12-04" @default.
• W1791755430 modified "2023-10-17" @default.
• W1791755430 title "ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells" @default.
• W1791755430 cites W1968949976 @default.
• W1791755430 cites W1971236570 @default.
• W1791755430 cites W1977090021 @default.
• W1791755430 cites W1991069555 @default.
• W1791755430 cites W1996490076 @default.
• W1791755430 cites W2002998828 @default.
• W1791755430 cites W2004326614 @default.
• W1791755430 cites W2006057301 @default.
• W1791755430 cites W2028593825 @default.
• W1791755430 cites W2045832625 @default.
• W1791755430 cites W2051025382 @default.
• W1791755430 cites W2058759427 @default.
• W1791755430 cites W2064486198 @default.
• W1791755430 cites W2079298594 @default.
• W1791755430 cites W2082462837 @default.
• W1791755430 cites W2087207490 @default.
• W1791755430 cites W2096800294 @default.
• W1791755430 cites W2103555733 @default.
• W1791755430 cites W2104545571 @default.
• W1791755430 cites W2108333425 @default.
• W1791755430 cites W2115242278 @default.
• W1791755430 cites W2118035762 @default.
• W1791755430 cites W2121158863 @default.
• W1791755430 cites W2124540758 @default.
• W1791755430 cites W2137755195 @default.
• W1791755430 cites W2150782426 @default.
• W1791755430 cites W2151499633 @default.
• W1791755430 cites W2152516668 @default.
• W1791755430 cites W2154589460 @default.
• W1791755430 cites W2164049034 @default.
• W1791755430 cites W2167770231 @default.
• W1791755430 cites W2168471784 @default.
• W1791755430 doi "https://doi.org/10.18632/oncotarget.1449" @default.
• W1791755430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3964212" @default.
• W1791755430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24504051" @default.
• W1791755430 hasPublicationYear "2013" @default.
• W1791755430 type Work @default.
• W1791755430 sameAs 1791755430 @default.
• W1791755430 citedByCount "28" @default.
• W1791755430 countsByYear W17917554302014 @default.
• W1791755430 countsByYear W17917554302015 @default.
• W1791755430 countsByYear W17917554302016 @default.
• W1791755430 countsByYear W17917554302017 @default.
• W1791755430 countsByYear W17917554302018 @default.
• W1791755430 countsByYear W17917554302019 @default.
• W1791755430 countsByYear W17917554302020 @default.
• W1791755430 countsByYear W17917554302021 @default.
• W1791755430 countsByYear W17917554302022 @default.
• W1791755430 countsByYear W17917554302023 @default.
• W1791755430 crossrefType "journal-article" @default.
• W1791755430 hasAuthorship W1791755430A5012626021 @default.
• W1791755430 hasAuthorship W1791755430A5016198812 @default.
• W1791755430 hasAuthorship W1791755430A5029305848 @default.
• W1791755430 hasAuthorship W1791755430A5029609160 @default.
• W1791755430 hasAuthorship W1791755430A5035426042 @default.
• W1791755430 hasAuthorship W1791755430A5052795429 @default.
• W1791755430 hasAuthorship W1791755430A5071516377 @default.
• W1791755430 hasAuthorship W1791755430A5080023346 @default.
• W1791755430 hasAuthorship W1791755430A5091178280 @default.
• W1791755430 hasBestOaLocation W17917554301 @default.
• W1791755430 hasConcept C103796816 @default.
• W1791755430 hasConcept C118487528 @default.
• W1791755430 hasConcept C121608353 @default.
• W1791755430 hasConcept C126322002 @default.
• W1791755430 hasConcept C143998085 @default.
• W1791755430 hasConcept C1491633281 @default.
• W1791755430 hasConcept C194409129 @default.
• W1791755430 hasConcept C2778042024 @default.
• W1791755430 hasConcept C2779134260 @default.
• W1791755430 hasConcept C2780192828 @default.
• W1791755430 hasConcept C2780827179 @default.
• W1791755430 hasConcept C2780932548 @default.
• W1791755430 hasConcept C3008058167 @default.
• W1791755430 hasConcept C502942594 @default.
• W1791755430 hasConcept C524204448 @default.
• W1791755430 hasConcept C54355233 @default.
• W1791755430 hasConcept C71924100 @default.
• W1791755430 hasConcept C86803240 @default.
• W1791755430 hasConceptScore W1791755430C103796816 @default.
• W1791755430 hasConceptScore W1791755430C118487528 @default.
• W1791755430 hasConceptScore W1791755430C121608353 @default.
• W1791755430 hasConceptScore W1791755430C126322002 @default.
• W1791755430 hasConceptScore W1791755430C143998085 @default.
• W1791755430 hasConceptScore W1791755430C1491633281 @default.

• next